Paul Sugarbaker

Dr. Paul Sugarbaker

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

8 February 2005 in International Seminars in Surgical Oncology
Verified
Journal Article
Open access
PDF file
RHRhonda L Harmon
Rhonda L Harmon
PSPaul Sugarbaker
Paul Sugarbaker
Peritoneal carcinomatosis from gastrointestinal cancer has new treatment options for surgical management. The approach uses cytoreductive surgery which combines peritonectomy and visceral resection in an effort to remove all visible cancer within the abdomen and pelvis. Then the peritoneal cavity is flooded with chemotherapy solution in an attempt to eradicate residual disease. In order to select patients for this approach the quantitative prognostic indicators for carcinomatosis were reviewed, compared and contrasted. Prognostic indicators to be used to select patients for this aggressive approach at the initiation of surgery and after completion of cytoreduction were studied. Four quantitative assessments to be used at the time of abdominal exploration were the Gilly staging, Japanese gastric cancer P score, peritoneal cancer index (PCI), and the simplified peritoneal cancer index (SPCI). All have value with the PCI being the most validated and most precise. Preoperative assessments include the tumor histopathology and the prior surgical score. The completeness of cytoreduction score is an assessment of residual disease after a maximal surgical effort. An opportunity for long-term survival following treatment for carcinomatosis requires a complete cytoreduction in all reports for gastrointestinal cancer. Quantitative prognostic indicators need to be knowledgeably employed when patients with carcinomatosis are being treated. Improved patient selection with greater benefit and reduced morbidity and mortality should result.

27 November 2006 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
TYT.D. Yan
T.D. Yan
LWL. Welch
L. Welch
DBD. Black
D. Black
PSPaul Sugarbaker
Paul Sugarbaker
Background: In the past, diffuse malignant peritoneal mesothelioma (DMPM) was regarded as a preterminal condition. The length of survival was dependent upon the aggressive versus indolent biologic behavior of the neoplasm. The overall median survival was ∼1 year after systemic chemotherapy. Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been used as a treatment alternative, but the efficacy of this combined treatment remains to be established. Patients and methods: Searches for relevant studies published in peer-reviewed medical journals on CRS and PIC for DMPM before May 2006 were carried out on six databases. The reference lists of all retrieved articles were reviewed for further identification of potentially relevant studies. Expert academic surgeons in Washington, DC, USA were asked whether they knew about any important unpublished data. Two investigators independently evaluated each study according to predefined criteria. The quality of each study was assessed. Clinical effectiveness was synthesized through a narrative review with full tabulation of results of all included studies. Results: Seven prospective observational studies from six tertiary institutions were available, allowing 240 DMPM patients for assessment. The median survival ranged from 34–92 months. The 1-, 3- and 5-year survival varied from 60% to 88%, 43% to 65% and 29% to 59%, respectively. The perioperative morbidity varied from 25% to 40% and mortality ranged from 0% to 8%. Conclusions: This systematic review evaluated the current evidence for CRS and PIC for DMPM. Seven observational studies were available for assessment, which demonstrated an improved overall survival, as compared to historical controls, using systemic chemotherapy and palliative surgery.

8 January 2004 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SGS. González‐Moreno
S. González‐Moreno
PSPaul Sugarbaker
Paul Sugarbaker

12 October 2006 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TYTristan D. Yan
Tristan D. Yan
DBDeborah Black
Deborah Black
RSRenaldo Savady
Renaldo Savady
PSPaul Sugarbaker
Paul Sugarbaker

10 March 2006 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
PSPaul Sugarbaker
Paul Sugarbaker
RARobert Alderman
Robert Alderman
GEGary Edwards
Gary Edwards
CMChristina Ellen Marquardt
Christina Ellen Marquardt
VGVadim Gushchin
Vadim Gushchin
DCDavid Chang
David Chang